HUT74900A - Treatment of autoimmune disease using oral tolerization and/or type i interferon - Google Patents

Treatment of autoimmune disease using oral tolerization and/or type i interferon Download PDF

Info

Publication number: HUT74900A
Authority: HU; Hungary
Prior art keywords: interferon; antigen; disease; mbp; cells
Prior art date: 1994-04-08

Application number

HU9602750A

Other languages

English (en)

Hungarian (hu)

Other versions

HU9602750D0 (en

Inventor

David A Hafler

Howard L Weiner

Original Assignee

Brigham & Womens Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-08

Filing date

1995-04-07

Publication date

1997-02-28

1995-04-07 Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital

1996-11-28 Publication of HU9602750D0 publication Critical patent/HU9602750D0/hu

1997-02-28 Publication of HUT74900A publication Critical patent/HUT74900A/hu

Links

208000023275 Autoimmune disease Diseases 0.000 title claims description 61
102000002227 Interferon Type I Human genes 0.000 title claims description 14
108010014726 Interferon Type I Proteins 0.000 title claims description 14
238000011282 treatment Methods 0.000 title description 63
239000000427 antigen Substances 0.000 claims description 140
108091007433 antigens Proteins 0.000 claims description 140
102000036639 antigens Human genes 0.000 claims description 140
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 claims description 79
108090000467 Interferon-beta Proteins 0.000 claims description 69
102000003996 Interferon-beta Human genes 0.000 claims description 68
201000010099 disease Diseases 0.000 claims description 68
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 68
230000000694 effects Effects 0.000 claims description 65
108090000765 processed proteins & peptides Proteins 0.000 claims description 52
210000001744 T-lymphocyte Anatomy 0.000 claims description 50
229960001388 interferon-beta Drugs 0.000 claims description 42
238000000034 method Methods 0.000 claims description 41
201000006417 multiple sclerosis Diseases 0.000 claims description 36
241000124008 Mammalia Species 0.000 claims description 33
102000004196 processed proteins & peptides Human genes 0.000 claims description 33
239000012634 fragment Substances 0.000 claims description 30
238000010171 animal model Methods 0.000 claims description 22
241000282414 Homo sapiens Species 0.000 claims description 16
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
206010039073 rheumatoid arthritis Diseases 0.000 claims description 13
229920001184 polypeptide Polymers 0.000 claims description 12
206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 11
108060003199 Glucagon Proteins 0.000 claims description 9
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 9
229960004666 glucagon Drugs 0.000 claims description 9
108090001061 Insulin Proteins 0.000 claims description 8
102000004877 Insulin Human genes 0.000 claims description 8
238000006243 chemical reaction Methods 0.000 claims description 8
229940125396 insulin Drugs 0.000 claims description 8
102000000503 Collagen Type II Human genes 0.000 claims description 7
108010041390 Collagen Type II Proteins 0.000 claims description 7
230000001404 mediated effect Effects 0.000 claims description 7
101710137302 Surface antigen S Proteins 0.000 claims description 6
230000006472 autoimmune response Effects 0.000 claims description 5
102000012422 Collagen Type I Human genes 0.000 claims description 4
108010022452 Collagen Type I Proteins 0.000 claims description 4
102000001187 Collagen Type III Human genes 0.000 claims description 4
108010069502 Collagen Type III Proteins 0.000 claims description 4
108010010974 Proteolipids Proteins 0.000 claims description 4
102000016202 Proteolipids Human genes 0.000 claims description 4
241000283984 Rodentia Species 0.000 claims description 4
230000008569 process Effects 0.000 claims description 3
241000894007 species Species 0.000 claims description 3
101001054334 Homo sapiens Interferon beta Proteins 0.000 claims description 2
229940096422 collagen type i Drugs 0.000 claims description 2
102400000321 Glucagon Human genes 0.000 claims 1
102000001617 Interferon Receptors Human genes 0.000 claims 1
108010054267 Interferon Receptors Proteins 0.000 claims 1
230000001419 dependent effect Effects 0.000 claims 1
238000003745 diagnosis Methods 0.000 claims 1
102000029752 retinol binding Human genes 0.000 claims 1
108091000053 retinol binding Proteins 0.000 claims 1
238000011808 rodent model Methods 0.000 claims 1
102000047918 Myelin Basic Human genes 0.000 description 72
101710107068 Myelin basic protein Proteins 0.000 description 72
210000004027 cell Anatomy 0.000 description 62
201000002491 encephalomyelitis Diseases 0.000 description 57
241000700159 Rattus Species 0.000 description 56
229940079322 interferon Drugs 0.000 description 53
102000014150 Interferons Human genes 0.000 description 52
108010050904 Interferons Proteins 0.000 description 52
230000001629 suppression Effects 0.000 description 48
241000700199 Cavia porcellus Species 0.000 description 36
241001465754 Metazoa Species 0.000 description 31
210000001519 tissue Anatomy 0.000 description 28
241000699666 Mus <mouse, genus> Species 0.000 description 25
241000699670 Mus sp. Species 0.000 description 24
230000020192 tolerance induction in gut-associated lymphoid tissue Effects 0.000 description 24
108010074328 Interferon-gamma Proteins 0.000 description 23
101001018322 Sus scrofa Myelin basic protein Proteins 0.000 description 23
102000004887 Transforming Growth Factor beta Human genes 0.000 description 22
108090001012 Transforming Growth Factor beta Proteins 0.000 description 22
208000024891 symptom Diseases 0.000 description 22
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 22
102000008070 Interferon-gamma Human genes 0.000 description 21
230000001363 autoimmune Effects 0.000 description 18
230000006470 autoimmune attack Effects 0.000 description 18
230000009467 reduction Effects 0.000 description 18
239000000126 substance Substances 0.000 description 18
102000004127 Cytokines Human genes 0.000 description 16
108090000695 Cytokines Proteins 0.000 description 16
230000001939 inductive effect Effects 0.000 description 16
102000004388 Interleukin-4 Human genes 0.000 description 15
108090000978 Interleukin-4 Proteins 0.000 description 15
229940028885 interleukin-4 Drugs 0.000 description 15
206010011968 Decreased immune responsiveness Diseases 0.000 description 14
230000028993 immune response Effects 0.000 description 14
238000007912 intraperitoneal administration Methods 0.000 description 14
101000982009 Bos taurus Myelin proteolipid protein Proteins 0.000 description 13
238000011694 lewis rat Methods 0.000 description 13
230000007246 mechanism Effects 0.000 description 13
239000002953 phosphate buffered saline Substances 0.000 description 13
108090000174 Interleukin-10 Proteins 0.000 description 12
102000003814 Interleukin-10 Human genes 0.000 description 12
229940044627 gamma-interferon Drugs 0.000 description 12
210000000987 immune system Anatomy 0.000 description 12
230000003053 immunization Effects 0.000 description 12
229940076144 interleukin-10 Drugs 0.000 description 12
230000001105 regulatory effect Effects 0.000 description 12
241000282412 Homo Species 0.000 description 11
206010012601 diabetes mellitus Diseases 0.000 description 11
238000002649 immunization Methods 0.000 description 11
230000006698 induction Effects 0.000 description 11
210000000056 organ Anatomy 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
230000004044 response Effects 0.000 description 11
230000001506 immunosuppresive effect Effects 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
150000001413 amino acids Chemical group 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
230000002519 immonomodulatory effect Effects 0.000 description 9
229960003130 interferon gamma Drugs 0.000 description 9
229940047124 interferons Drugs 0.000 description 9
102000051325 Glucagon Human genes 0.000 description 8
241000187479 Mycobacterium tuberculosis Species 0.000 description 8
206010033799 Paralysis Diseases 0.000 description 8
239000002671 adjuvant Substances 0.000 description 8
238000003556 assay Methods 0.000 description 8
238000002648 combination therapy Methods 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
238000001990 intravenous administration Methods 0.000 description 8
238000007911 parenteral administration Methods 0.000 description 8
210000004989 spleen cell Anatomy 0.000 description 8
238000007920 subcutaneous administration Methods 0.000 description 8
101001018362 Bos taurus Myelin basic protein Proteins 0.000 description 7
108700018351 Major Histocompatibility Complex Proteins 0.000 description 7
241001529936 Murinae Species 0.000 description 7
229940079593 drug Drugs 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
210000003289 regulatory T cell Anatomy 0.000 description 7
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 7
230000002195 synergetic effect Effects 0.000 description 7
241000283690 Bos taurus Species 0.000 description 6
102000008186 Collagen Human genes 0.000 description 6
108010035532 Collagen Proteins 0.000 description 6
102000006992 Interferon-alpha Human genes 0.000 description 6
102000006386 Myelin Proteins Human genes 0.000 description 6
108010083674 Myelin Proteins Proteins 0.000 description 6
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 6
230000000961 alloantigen Effects 0.000 description 6
206010003246 arthritis Diseases 0.000 description 6
229920001436 collagen Polymers 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000451 tissue damage Effects 0.000 description 6
231100000827 tissue damage Toxicity 0.000 description 6
230000005951 type IV hypersensitivity Effects 0.000 description 6
208000027930 type IV hypersensitivity disease Diseases 0.000 description 6
108010047761 Interferon-alpha Proteins 0.000 description 5
101710137010 Retinol-binding protein 3 Proteins 0.000 description 5
102100038247 Retinol-binding protein 3 Human genes 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
238000004140 cleaning Methods 0.000 description 5
238000011284 combination treatment Methods 0.000 description 5
230000006378 damage Effects 0.000 description 5
210000005012 myelin Anatomy 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000012546 transfer Methods 0.000 description 5
208000009386 Experimental Arthritis Diseases 0.000 description 4
108010004889 Heat-Shock Proteins Proteins 0.000 description 4
206010062016 Immunosuppression Diseases 0.000 description 4
101001018320 Mus musculus Myelin basic protein Proteins 0.000 description 4
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
230000002354 daily effect Effects 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000003414 extremity Anatomy 0.000 description 4
230000004957 immunoregulator effect Effects 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
239000000411 inducer Substances 0.000 description 4
230000003902 lesion Effects 0.000 description 4
229920006008 lipopolysaccharide Polymers 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
230000008961 swelling Effects 0.000 description 4
210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
108010062580 Concanavalin A Proteins 0.000 description 3
102000008214 Glutamate decarboxylase Human genes 0.000 description 3
108091022930 Glutamate decarboxylase Proteins 0.000 description 3
102000003886 Glycoproteins Human genes 0.000 description 3
108090000288 Glycoproteins Proteins 0.000 description 3
208000030836 Hashimoto thyroiditis Diseases 0.000 description 3
102000002812 Heat-Shock Proteins Human genes 0.000 description 3
108010033040 Histones Proteins 0.000 description 3
101001135737 Mus musculus Parathyroid hormone-related protein Proteins 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
210000003563 lymphoid tissue Anatomy 0.000 description 3
239000000463 material Substances 0.000 description 3
210000003205 muscle Anatomy 0.000 description 3
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
210000000496 pancreas Anatomy 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
208000016192 Demyelinating disease Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
206010023232 Joint swelling Diseases 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
101000981991 Mus musculus Myelin proteolipid protein Proteins 0.000 description 2
101000619799 Mus musculus Peroxiredoxin-5, mitochondrial Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
208000012902 Nervous system disease Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000000612 antigen-presenting cell Anatomy 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
238000011970 concomitant therapy Methods 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
230000008004 immune attack Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
210000001503 joint Anatomy 0.000 description 2
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
206010028417 myasthenia gravis Diseases 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000035764 nutrition Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000002516 postimmunization Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
238000011160 research Methods 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
201000000596 systemic lupus erythematosus Diseases 0.000 description 2
238000013518 transcription Methods 0.000 description 2
230000035897 transcription Effects 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
230000004304 visual acuity Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
241000700198 Cavia Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
102000011799 Desmoglein Human genes 0.000 description 1
108050002238 Desmoglein Proteins 0.000 description 1
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
108010071289 Factor XIII Proteins 0.000 description 1
208000011514 Familial renal glucosuria Diseases 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
108010075704 HLA-A Antigens Proteins 0.000 description 1
102000006354 HLA-DR Antigens Human genes 0.000 description 1
108010058597 HLA-DR Antigens Proteins 0.000 description 1
102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
102000029746 Histidine-tRNA Ligase Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
101000843187 Homo sapiens Histidine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108010005714 Interferon beta-1b Proteins 0.000 description 1
241001233242 Lontra Species 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
108700005092 MHC Class II Genes Proteins 0.000 description 1
102000043129 MHC class I family Human genes 0.000 description 1
108091054437 MHC class I family Proteins 0.000 description 1
208000007466 Male Infertility Diseases 0.000 description 1
208000010428 Muscle Weakness Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
102000055324 Myelin Proteolipid Human genes 0.000 description 1
108700021862 Myelin Proteolipid Proteins 0.000 description 1
201000002481 Myositis Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
241000721454 Pemphigus Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
206010037714 Quadriplegia Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
208000012658 Skin autoimmune disease Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
208000037908 antibody-mediated disorder Diseases 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
201000004982 autoimmune uveitis Diseases 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
229940021459 betaseron Drugs 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000008512 biological response Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000009849 deactivation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
230000009266 disease activity Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002222 downregulating effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
239000003797 essential amino acid Substances 0.000 description 1
235000020776 essential amino acid Nutrition 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000000763 evoking effect Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000003631 expected effect Effects 0.000 description 1
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
229940012444 factor xiii Drugs 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000005021 gait Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000012010 growth Effects 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
238000002664 inhalation therapy Methods 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000004324 lymphatic system Anatomy 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
238000005457 optimization Methods 0.000 description 1
238000007410 oral glucose tolerance test Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000009696 proliferative response Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
108700000734 rat La Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
208000007278 renal glycosuria Diseases 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000013077 scoring method Methods 0.000 description 1
238000012216 screening Methods 0.000 description 1
235000014102 seafood Nutrition 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
VIDRYROWYFWGSY-UHFFFAOYSA-N sotalol hydrochloride Chemical compound Cl.CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 VIDRYROWYFWGSY-UHFFFAOYSA-N 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Hematology (AREA)
Biophysics (AREA)
Ophthalmology & Optometry (AREA)
Toxicology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Rehabilitation Therapy (AREA)
Pain & Pain Management (AREA)
Microbiology (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)

HU9602750A 1994-04-08 1995-04-07 Treatment of autoimmune disease using oral tolerization and/or type i interferon HUT74900A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US22537294A	1994-04-08	1994-04-08

Publications (2)

Publication Number	Publication Date
HU9602750D0 HU9602750D0 (en)	1996-11-28
HUT74900A true HUT74900A (en)	1997-02-28

Family

ID=22844605

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HU9602750A HUT74900A (en)	1994-04-08	1995-04-07	Treatment of autoimmune disease using oral tolerization and/or type i interferon

Country Status (9)

Country	Link
EP (1)	EP0752880A4 (fr)
JP (1)	JPH09511745A (fr)
AU (1)	AU686797B2 (fr)
BR (1)	BR9507451A (fr)
CA (1)	CA2185353A1 (fr)
HU (1)	HUT74900A (fr)
IL (1)	IL113303A0 (fr)
NO (1)	NO964199D0 (fr)
WO (1)	WO1995027499A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5906816A (en) *	1995-03-16	1999-05-25	University Of Florida	Method for treatment of autoimmune diseases
US6372206B1 (en)	1989-03-02	2002-04-16	University Of Florida	Orally-administered interferon-TAU compositions and methods
CZ122697A3 (en) *	1994-10-25	1997-09-17	Immulogic Pharma Corp	Preparations and methods of treating disseminated sclerosis
JP4878664B2 (ja) *	1996-12-24	2012-02-15	バイオジェン・アイデック・エムエイ・インコーポレイテッド	安定な液体インターフェロン処方物
JP2001511187A (ja) *	1997-02-28	2001-08-07	エンゾーセラピュウティクス，インコーポレイテッド	選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
AU736282B2 (en)	1997-03-21	2001-07-26	Chugai Seiyaku Kabushiki Kaisha	A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en)	2000-03-15	2001-09-24	The Brigham And Women's Hospital, Inc.	Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de)	2000-05-24	2007-08-15	Us Health	E-selectin zur behandlung oder vorbeugung von schlaganfall
JPWO2004058295A1 (ja) *	2002-12-26	2006-04-27	第一アスビオファーマ株式会社	類天疱瘡治療剤
WO2008130382A2 (fr)	2006-10-31	2008-10-30	East Carolina University	Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
CA2757287C (fr) *	2009-03-31	2019-09-10	East Carolina University	Cytokines et neuroantigenes utilises dans le traitement de maladies immunitaires
JP6590330B2 (ja) *	2013-11-11	2019-10-16	キッコーマン株式会社	経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en)	2019-04-04	2019-05-22	Orexo Ab	New pharmaceutical compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2844889A (en) *	1988-01-22	1989-07-27	Collagen Corporation	Method for suppressing the growth of normal and cancer cells
KR950700082A (ko) *	1992-02-28	1995-01-16	로버트 씨. 비숍	바이스탠더(bystander)에 의한 자가면역질환을 처치하는 방법

1995
- 1995-04-07 EP EP95916183A patent/EP0752880A4/fr not_active Withdrawn
- 1995-04-07 HU HU9602750A patent/HUT74900A/hu active IP Right Revival
- 1995-04-07 WO PCT/US1995/004120 patent/WO1995027499A1/fr not_active Ceased
- 1995-04-07 CA CA002185353A patent/CA2185353A1/fr not_active Abandoned
- 1995-04-07 IL IL11330395A patent/IL113303A0/xx unknown
- 1995-04-07 AU AU22776/95A patent/AU686797B2/en not_active Ceased
- 1995-04-07 BR BR9507451A patent/BR9507451A/pt unknown
- 1995-04-07 JP JP7526403A patent/JPH09511745A/ja active Pending
1996
- 1996-10-03 NO NO964199A patent/NO964199D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1995027499A1 (fr)	1995-10-19
EP0752880A4 (fr)	2000-08-09
AU2277695A (en)	1995-10-30
EP0752880A1 (fr)	1997-01-15
CA2185353A1 (fr)	1995-10-19
BR9507451A (pt)	1997-08-05
AU686797B2 (en)	1998-02-12
IL113303A0 (en)	1995-07-31
JPH09511745A (ja)	1997-11-25
HU9602750D0 (en)	1996-11-28
NO964199L (no)	1996-10-03
NO964199D0 (no)	1996-10-03

Legal Events

Date	Code	Title
1999-01-28	DFD9	Temporary protection cancelled due to non-payment of fee
1999-03-01	DNF4	Restoration of lapsed final protection
2001-01-29	DFD9	Temporary protection cancelled due to non-payment of fee

Publication	Publication Date	Title
EP0627933B1 (fr)	2002-11-27	Suppression de maladies auto-immunes par des antigenes en attente
US6645504B1 (en)	2003-11-11	Bystander suppression of type I diabetes by oral administration of glucagon
US6036957A (en)	2000-03-14	Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US5935577A (en)	1999-08-10	Treatment of autoimmune disease using tolerization in combination with methotrexate
HUP0001960A2 (hu)	2000-10-28	Metotrexát kombináció autoimmun tünetek befolyásolására
HUT61487A (en)	1993-01-28	Process for producing aerosol pharmaceutical composition comprising autoantigens
HU210813A9 (en)	1995-08-28	Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
WO1998032451A9 (fr)	1998-12-30	Traitement des maladies auto-immunes a l'aide d'une tolerance induite en combinaison avec du methotrexate
US20050202032A1 (en)	2005-09-15	Use of neglected target tissue antigens in modulation of immune responses
HUT74900A (en)	1997-02-28	Treatment of autoimmune disease using oral tolerization and/or type i interferon
HUT76101A (en)	1997-06-30	Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US20010007758A1 (en)	2001-07-12	Treatment of multiple sclerosis using COP-1 and Th2-enhancing cytokines
US20040115217A1 (en)	2004-06-17	Bystander suppression of autoimmune diseases
Virella et al.	2019	Organ-specific autoimmune diseases